MITOXCEL
Live / Applied — Response to non-final action entered (as of 16 Mar 2026)
What this means for you
Not registered yet, but its 12 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99230621
- Mark type
- Stylized text
- Filed
- 12 Jun 2025
- Attorney of record
- Jared L. DuJack
Goods and services
- Class 005 — Pharmaceuticals: Synthesized peptides for the treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for the prevention of and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Pharmaceutical preparations for gene therapy for the treatment of age-related disorders; Pharmaceutical preparations for gene therapy for the treatment of cancer; Medicated skin preparation for use in treating skin conditions, aging, mitochondrial conditions, and senescent cells
- Class 042 — Scientific and technological services: Medical research services; Medical research in the field of mitochondrial health and mitochondrial disease; Medical research services in the field of metabolic health and metabolic conditions; Medical research services in the field of anti-aging; Medical research services in the field of senescent cells; Medical research services in the field of age-related disorders; Medical research services in the field of neurodegenerative health and neurodegenerative disease; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Gene therapy research; Testing of pharmaceuticals for cell and gene therapies; Development of pharmaceuticals for cell and gene therapies; Pharmaceutical research in the field of mitochondrial disease; Pharmaceutical research in the field of metabolic conditions; Pharmaceutical research in the field of neurodegenerative disease
- Class 044 — Medical, beauty and agricultural services: Medical services, namely, anti-aging services; Medical services, namely, providing preventative care and treatment of cancer, age-related disorders, age-related diseases, skin conditions, radiation damage, obesity, mitochondrial disease, neurodegenerative disease, and metabolic conditions; Medical services in the field of mitochondrial health and mitochondrial disease; Medical services in the field of metabolic health and metabolic conditions; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical services in the field of neurodegenerative health and neurodegenerative disease; Medical advisory services; Medical testing services; Medical testing services relating to the diagnosis and treatment of disease
Owner
- SENOTHERAPEUTIX, Inc., Surfside, FL, US
Prosecution history
- 16 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 15 Dec 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 15 Dec 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 17 Sept 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 Sept 2025 — NON-FINAL ACTION E-MAILED
- 17 Sept 2025 — NON-FINAL ACTION WRITTEN
- 10 Sept 2025 — ASSIGNED TO EXAMINER
- 15 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 12 Jun 2025 — NEW APPLICATION ENTERED